<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区
          Global EditionASIA 中文雙語Fran?ais
          World
          Home / World / Europe

          Low level of virus in UK impacts trials

          By ANGUS MCNEICE in London | China Daily Global | Updated: 2020-06-25 17:03
          Share
          Share - WeChat

          United Kingdom researchers are having to test COVID-19 vaccines abroad because novel coronavirus levels are too low in the British population, a UK parliamentary committee heard this week.

          Human trials for ChAdOx1 nCoV-19, which is more commonly known as the Oxford vaccine, will commence this week in South Africa, where the number of COVID-19 cases has risen rapidly in June. The Oxford vaccine will also enter human trials later this year in the United States.

          Meanwhile, developers of a separate vaccine at Imperial College London are looking to launch human trials in Brazil, a country that has contended with a comparatively high transmission rate for several months. Human trials for the Oxford vaccine have already begun in Brazil.

          Moving human trials abroad is necessary because, in the UK, not enough people would come into contact with the virus to challenge vaccine efficacy, according to Sarah Gilbert, a professor of vaccinology at Oxford University who is leading the development of ChAdOx1 nCoV-19.

          Gilbert and her colleagues had been hoping to get preliminary results from UK human trials in April. However, transmission was so high in March that the UK went into lockdown.

          Movement restrictions in the UK then drove down the transmission rate to the point where human trials would have "little chance of determining efficacy" in a vaccine, Gilbert said. The Oxford team has now had to look abroad, and multiple countries have come forward.

          "There hasn't been any lack of other countries wanting to partner with us," Gilbert told the House of Lords Science and Technology Committee. "We have chosen to work with Brazil because of previous experience of working with the clinical trial team there."

          Immunologist Robin Shattock, who is leading the development of a vaccine at Imperial College London, said he is also targeting Brazil for human trials.

          "We hopefully will look to do the same," Shattock said. "It's really about getting those numbers to be able to show that the vaccine works."

          Gilbert said that pharmaceutical company AstraZeneca, which is partnering on the Oxford vaccine, is hoping to coordinate a US-based trial involving 30,000 people "in the coming months". The exact location in the US will be based on virus transmission rates.

          Picking a country or region for testing is further complicated due to the timeline of a trial, according to Gilbert. In an ideal world, virus transmission would be high in a region several weeks after people have been given the vaccine, allowing time for them to develop antibodies and other immune responses stimulated by the inoculation.

          "The problem for us is not knowing where virus transmission is now, it's knowing where it's going to be in four to six weeks' time," Gilbert said.

          Some experts believe that alternative — and more controversial — forms of vaccine trials should be explored, given the challenges associated with conventional field testing. London-based lab hVIVO is looking to gain approval from UK drug regulators to run so-called human challenge trials, where paid volunteers are intentionally exposed to the virus in order to test vaccine protection.

          Cathal Friel, chief executive of hVIVO parent company Open Orphan, told China Daily that opening up such trials "has to be one of the options considered".

          Most Viewed in 24 Hours
          Top
          BACK TO THE TOP
          English
          Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
          License for publishing multimedia online 0108263

          Registration Number: 130349
          FOLLOW US
          主站蜘蛛池模板: 男女扒开双腿猛进入爽爽免费看| 亚洲综合黄色的在线观看| 亚洲高清aⅴ日本欧美视频| 18av千部影片| 人妻偷拍一区二区三区| 成人无号精品一区二区三区| 亚洲欧美人成电影在线观看| 国产成人av乱码在线观看| 亚洲天堂伊人久久a成人| 国产一区二区三区黄色片| 成在人线av无码免费看网站直播| 人妻少妇精品性色av蜜桃| 国产亚洲精品资源在线26u| 亚洲午夜无码久久久久蜜臀av| 亚洲国产综合亚洲综合国产| 日韩精品一区二区蜜臀av| 欧洲无码一区二区三区在线观看 | 欧美伊人亚洲伊人色综| 白嫩少妇无套内谢视频| 久久夜色精品国产爽爽 | 狠狠色狠狠综合久久| 国产精品VA尤物在线观看| 国产亚洲美女精品久久久| 国产国拍亚洲精品永久软件| 国产一区二区三区在线观看免费 | 国产区成人精品视频| av天堂久久精品影音先锋| 老鸭窝| 色色97| 露脸一二三区国语对白| 天下第一社区在线观看| 在线高清免费不卡全码| 欧美乱妇高清无乱码在线观看 | 亚洲一区二区三区18禁| 欧美国产精品不卡在线观看| 亚洲av不卡电影在线网址最新| 男同精品视频免费观看网站| 国产一区二区精品高清在线观看 | 女主播扒开屁股给粉丝看尿口| 国产三级精品片| 久久久欧美国产精品人妻噜噜|